Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Aug 30;17(1):433.
doi: 10.1186/s12906-017-1933-7.

A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

Angèle Guilbot  1 , Marie Bangratz  2 , Samira Ait Abdellah  2 , Christian Lucas  3
Affiliations
Observational Study

A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

Angèle Guilbot et al. BMC Complement Altern Med. .

Abstract

Background: Feverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study.

Methods: Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.

Results: Supplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated.

Conclusions: Results suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study.

Trial registration: ClinicalTrials.gov: NCT02901756 , retrospectively registered on August 24, 2016.

Keywords: Coenzyme Q10; Feverfew; Magnesium; Migraine.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the French Advisory Committee on Information Processing in Material Research in the Field of Health and the French National Commission on Informatics and Liberty. The study was performed in accordance with the ethical standards laid down in the Declaration of Helsinki and the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines. All patients gave their informed written consent prior to study participation.

Consent for publication

Not applicable.

Competing interests

AG, MB and SAA are respectively, Manager of the scientific department, Research project manager and Clinical project manager at PiLeJe. CL received fees from PiLeJe for advice on the study design and his contribution in the writing of this manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Disposition of patients and data sets
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55:21–34. doi: 10.1111/head.12482. - DOI - PubMed
    1. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11:289–299. doi: 10.1007/s10194-010-0217-0. - DOI - PMC - PubMed
    1. Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C. Migraine and probable migraine--results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia. 2005;25:1146–1158. doi: 10.1111/j.1468-2982.2005.00977.x. - DOI - PubMed
    1. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16:968–981. doi: 10.1111/j.1468-1331.2009.02748.x. - DOI - PubMed
    1. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4:CD002286. - PMC - PubMed

Publication types

Associated data